Tags

Type your tag names separated by a space and hit enter

Endocannabinoid System in Neurological Disorders.
Recent Pat CNS Drug Discov 2016; 10(2):90-112RP

Abstract

BACKGROUND

Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others.

METHODS

In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease and discuss the main findings about the use of cannabinoids in the therapy of these pathologies.

RESULTS

Despite different etiologies, neurodegenerative disorders exhibit similar mechanisms like neuro-inflammation, excitotoxicity, deregulation of intercellular communication, mitochondrial dysfunction and disruption of brain tissue homeostasis. Current treatments ameliorate the symptoms but are not curative. Interfering with the endocannabinoid signaling might be a valid therapeutic option in neuro-degeneration. To this aim, pharmacological intervention to modulate the endocannabinoid system and the use of natural and synthetic cannabimimetic drugs have been assessed. CB1 and CB2 receptor signaling contributes to the control of Ca2+ homeostasis, trophic support, mitochondrial activity, and inflammatory conditions.

CONCLUSION

Several studies and patents suggest that the endocannabinoid system has neuro-protective properties and might be a target in neurodegenerative diseases.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableDepartment of Medicine and Surgery, University of Salerno, Via Salvatore Allende, Baronissi, 84081 Salerno, Italy and Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 84084 Fisciano (Salerno)- Italy. annamaria.malfitano@unina.it.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27364363

Citation

Ranieri, Roberta, et al. "Endocannabinoid System in Neurological Disorders." Recent Patents On CNS Drug Discovery, vol. 10, no. 2, 2016, pp. 90-112.
Ranieri R, Laezza C, Bifulco M, et al. Endocannabinoid System in Neurological Disorders. Recent Pat CNS Drug Discov. 2016;10(2):90-112.
Ranieri, R., Laezza, C., Bifulco, M., Marasco, D., & Malfitano, A. M. (2016). Endocannabinoid System in Neurological Disorders. Recent Patents On CNS Drug Discovery, 10(2), pp. 90-112.
Ranieri R, et al. Endocannabinoid System in Neurological Disorders. Recent Pat CNS Drug Discov. 2016;10(2):90-112. PubMed PMID: 27364363.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoid System in Neurological Disorders. AU - Ranieri,Roberta, AU - Laezza,Chiara, AU - Bifulco,Maurizio, AU - Marasco,Daniela, AU - Malfitano,Anna M, PY - 2015/12/20/received PY - 2016/02/22/revised PY - 2016/02/23/accepted PY - 2016/7/2/pubmed PY - 2017/7/14/medline PY - 2016/7/2/entrez SP - 90 EP - 112 JF - Recent patents on CNS drug discovery JO - Recent Pat CNS Drug Discov VL - 10 IS - 2 N2 - BACKGROUND: Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others. METHODS: In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease and discuss the main findings about the use of cannabinoids in the therapy of these pathologies. RESULTS: Despite different etiologies, neurodegenerative disorders exhibit similar mechanisms like neuro-inflammation, excitotoxicity, deregulation of intercellular communication, mitochondrial dysfunction and disruption of brain tissue homeostasis. Current treatments ameliorate the symptoms but are not curative. Interfering with the endocannabinoid signaling might be a valid therapeutic option in neuro-degeneration. To this aim, pharmacological intervention to modulate the endocannabinoid system and the use of natural and synthetic cannabimimetic drugs have been assessed. CB1 and CB2 receptor signaling contributes to the control of Ca2+ homeostasis, trophic support, mitochondrial activity, and inflammatory conditions. CONCLUSION: Several studies and patents suggest that the endocannabinoid system has neuro-protective properties and might be a target in neurodegenerative diseases. SN - 2212-3954 UR - https://www.unboundmedicine.com/medline/citation/27364363/Endocannabinoid_System_in_Neurological_Disorders_ L2 - http://www.eurekaselect.com/144044/article DB - PRIME DP - Unbound Medicine ER -